9 results about "Oxyntomodulin" patented technology

Provided herein are novel N- and C-terminal oxyntomodulin polypeptide binding molecules, and uses thereof, including a method for quantitating oxyntomodulin.

Disclosed herein are novel modulators for GIPR, GLP-1R and / or GCGR. Specifically, provided herein are antibodies that specifically bind GIPR, oxyntomodulin analog peptides, and antibody- peptide conjugates (APCs) comprising an anti-GIPR antibody and an agonist for GLP-1R and / or GCGR (e.g., oxyntomodulin analog). Pharmaceutical compositions comprising these modulators disclosed herein, as well as uses thereof in treating metabolic conditions and disorders, such as diabetes (e.g., type 2 diabetes), NASH, overweight, and obesity are also provided.

Disclosed herein are novel modulators of GIPR, GLP-1R, and / or GCGR. In particular, provided herein are antibodies, oxyntomodulin analogue peptides, and antibody-peptide conjugates (APC) that specifically bind to GIPR, the antibody-peptide conjugates comprising an anti-GIPR antibody and an agonist of GLP-1R and / or GCGR (e.g., oxyntomodulin analogue). Also provided are pharmaceutical compositions comprising these modulators disclosed herein, and the use of the pharmaceutical compositions in the treatment of metabolic conditions and disorders, such as diabetes (e.g., type 2 diabetes), NASH, overweight, and obesity.

The present invention relates to GLP-1 and / or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and / or obesity or associated diseases or disorders.

The present invention relates to compounds comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib), each comprising an N-terminal modification group A comprising a biodistribution modulator, where the N-terminal modification group A is linked to Xaa1, and each comprising a C-terminal group C-terminal comprising a biodistribution modulator, where the C-terminal group C-terminal is linked to Xaa11. (Ia) and (Ib).

Described herein are new modified oxyntomodulin (OXM) complexes. The application further provides new methods of treating diseases or conditions, such as metabolic syndrome, diabetes, obesity, and cardiovascular disease, for example, using the new modified OXM complexes.

Described herein are new modified oxyntomodulin (OXM) complexes. The application further provides new methods of treating diseases or conditions, such as metabolic syndrome, diabetes, obesity, and cardiovascular disease, for example, using the new modified OXM complexes.

The present invention relates to a novel long-acting acylated oxyntomodulin analogue having dual GLP-1R / GlucagonR agonism and a pharmaceutical composition for preventing or treating obesity and overweight, or non-insulin dependent diabetes mellitus accompanied by obesity and overweight, comprising the same. The acylated oxyntomodulin analogue of the present invention comprises dual GLP-1 / Glucagon receptor agonism and has a very excellent improved in vivo half-life, and the pharmaceutical composition comprising the same can be used to treat metabolic diseases such as obesity and diabetes.

Disclosed herein are novel modulators for GIPR, GLP-1R and / or GCGR. Specifically, provided herein are antibodies that specifically bind GIPR, oxyntomodulin analog peptides, and antibody- peptide conjugates (APCs) comprising an anti-GIPR antibody and an agonist for GLP-1R and / or GCGR (e.g., oxyntomodulin analog). Pharmaceutical compositions comprising these modulators disclosed herein, as well as uses thereof in treating metabolic conditions and disorders, such as diabetes (e.g., type 2 diabetes), NASH, overweight, and obesity are also provided.